Author Bio
Dr. Orelli is a Senior Biotech Specialist. He has written about biotech, pharmaceutical, and medical device companies for The Motley Fool since 2007.
Follow @BiologyFool
Investors can get an early stake in Humacyte, the biotech developing human acellular vessels, by buying shares in
Alpha Healthcare Acquisition Corp. (NASDAQ:AHAC), the special acquisition company (SPAC) that plans to merge with Humacyte. In this video from
Motley Fool Live,
Feb.
22, Fool.com Contributors Brian Orelli and Keith Speights discuss Humacyte s prospects and whether it s more appropriate for a portfolio or a watch list.
Brian Orelli: Moving onto Humacyte, the company is going public through a merger with a special acquisition company (SPAC) called Alpha Healthcare Acquisition. Humacyte is developing a technique to take donor tissue and develop them into blood vessels that can then be used for a variety of uses, including something like dialysis or peripheral a
Human tissue developer Humacyte agrees to SPAC merger to go public reuters.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from reuters.com Daily Mail and Mail on Sunday newspapers.